Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Kronos Bio Inc (NQ: KRON )

1.380 +0.010 (+0.73%)
Streaming Delayed Price Updated: 11:28 AM EDT, Jul 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 57,177
Open 1.350
Bid (Size) 1.370 (4)
Ask (Size) 1.390 (3)
Prev. Close 1.370
Today's Range 1.345 - 1.400
52wk Range 0.6900 - 2.220
Shares Outstanding 56,769,091
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Kronos Bio Announces First Patient Dosed with KB-0742 in an Expansion Cohort Focused on Platinum-Resistant High-Grade Serous Ovarian Cancer
From Kronos Bio, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga

Performance

YTD
+15.00%
+15.00%
1 Month
+36.63%
+36.63%
3 Month
+45.26%
+45.26%
6 Month
+14.05%
+14.05%
1 Year
-29.59%
-29.59%

More News

Read More
Assertio Holdings And 2 Other Penny Stocks Insiders Are Buying
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Recap: Kronos Bio Q4 Earnings
Via Benzinga
Why NetEase Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
From Kronos Bio, Inc.
Via GlobeNewswire
Kronos Bio to Participate in Three Upcoming Healthcare Conferences and Events
From Kronos Bio, Inc.
Via GlobeNewswire
Kronos Bio Appoints Deborah Knobelman, Ph.D. as Chief Operating Officer and Chief Financial Officer
From Kronos Bio, Inc.
Via GlobeNewswire
KRON Stock Earnings: Kronos Bio Misses EPS, Beats Revenue for Q1 2024
Via InvestorPlace
Kronos Bio Reports First-Quarter 2024 Financial Results
From Kronos Bio, Inc.
Via GlobeNewswire
Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
From Kronos Bio, Inc.
Via GlobeNewswire
KRON Stock Earnings: Kronos Bio Beats EPS, Beats Revenue for Q4 2023
Via InvestorPlace
Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2023 Financial Results
From Kronos Bio, Inc.
Via GlobeNewswire
Kronos Bio Announces Restructuring to Focus Resources on Clinical Development with Extended Cash Runway
From Kronos Bio, Inc.
Via GlobeNewswire
Kronos Bio To Present Three Posters at AACR 2024 Annual Meeting
From Kronos Bio, Inc.
Via GlobeNewswire
Kronos Bio Announces Participation in 44th Annual Cowen Health Care Conference
From Kronos Bio, Inc.
Via GlobeNewswire
Kronos Bio Implements New Leadership Structure to Drive Pipeline Advancement
From Kronos Bio, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Cancer Player Kronos Bio To Stop Lanraplenib Combo Therapy Blood Cancer Study
Via Benzinga
Uber To Rally Over 13%? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga
Kronos Bio Announces Pipeline Update and p300 KAT Inhibitor Development Candidate
From Kronos Bio, Inc.
Via GlobeNewswire
Kronos Bio Announces Participation in H.C. Wainwright 4th Annual Precision Oncology Virtual Conference
From Kronos Bio, Inc.
Via GlobeNewswire
Kronos Bio Announces Participation in 35th Annual Piper Sandler Healthcare Conference
From Kronos Bio, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.